ProMIS Neurosciences Inc. PMN
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a CNS/neurology/psychiatry drug developer. Its lead program, PMN310, is in Phase 1 for Early Alzheimer's disease. Its next catalyst on record is PMN310: Unblinded 12-month topline data from PRECISE-AD (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PMN310 — Unblinded 12-month topline data from PRECISE-AD (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PMN310 (PRECISE-AD Phase 1b MAD) | Alzheimer's disease | antibody | Phase 1 |
| PMN267 | ALS (misfolded TDP-43) | antibody | Pre-clinical |
| PMN442 | DLB, Parkinson's disease, synucleinopathies | antibody | Pre-clinical |
| PMN311 | Alzheimer's disease vaccine | vaccine | Pre-clinical |
| PMN440 | Synucleinopathies vaccine | vaccine | Pre-clinical |
| PMN260 | TDP-43 vaccine | vaccine | Pre-clinical |
Recent results and decisions
- Jul 28, 2026positive Blinded 6-month interim: 0/136 ARIA-E cases across all genotypes incl. APOE4 carriers; directional biomarker declines (pooled active+placebo).
PRECISE-AD: blinded pooled cohort (active + placebo, 3:1); 0/136 ARIA-E at 6-mo interim — observed, not projected.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.